Lentiviral vectors incorporating a human elongation factor 1[alpha] promoter for the treatment of canine leukocyte adhesion deficiency

• Published in: Gene therapy Vol. 17; no. 5; p. 672
• Main Authors: Nelson, E J R, Tuschong, L M, Hunter, M J, Bauer, T R, Burkholder, T H, Hickstein, D D
• Format: Journal Article
• Language: English
• Published: Houndmills Nature Publishing Group 01.05.2010
• Subjects: Cell adhesion & migration; Dogs; Gene expression; Gene therapy; Immunology; Leukocytes
• ISSN: 0969-7128; 1476-5462
• DOI: 10.1038/gt.2010.7

Canine leukocyte adhesion deficiency (CLAD) provides a unique large animal model for testing new therapeutic approaches for the treatment of children with leukocyte adhesion deficiency (LAD). In our CLAD model, we examined two different fragments of the human elongation factor 1alpha (EF1alpha) promoter (EF1alphaL, 1189 bp and EF1alphaS, 233 bp) driving the expression of canine CD18 in a self-inactivating (SIN) lentiviral vector. The EF1alphaS vector resulted in the highest levels of canine CD18 expression in CLAD CD34(+) cells in vitro. Subsequently, autologous CD34(+) bone marrow cells from four CLAD pups were transduced with the EF1alphaS vector and infused following a non-myeloablative dose of 200 cGy total-body irradiation. None of the CLAD pups achieved levels of circulating CD18(+) neutrophils sufficient to reverse the CLAD phenotype, and all four animals were euthanized because of infections within 9 weeks of treatment. These results indicate that the EF1alphaS promoter-driven CD18 expression in the context of a RRLSIN lentiviral vector does not lead to sufficient numbers of CD18(+) neutrophils in vivo to reverse the CLAD phenotype when used in a non-myeloablative transplant regimen in dogs. [PUBLICATION ABSTRACT]